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CHAPTER 24

Recent Developments in Alternatives to
Animal Testing
Katy Taylor
Director of Science and Regulatory Affairs, Cruelty Free International
(formerly BUAV) and the European Coalition to End Animal Experiments,
London, United Kingdom

1

Introduction to Alternative Methods

At least 115 million animals are thought to be used for scientific purposes every
year, worldwide (Taylor et al., 2008). Animals are typically used to test whether
an intervention will cause harm to humans or other animals of the same or
different species, i.e. safety testing; or whether it will work, i.e. efficacy test
ing. Interventions can include testing substances (such as cosmetic products,
industrial chemicals, drugs, pesticides, food additives, and biocides); medical
devices; surgical techniques; environmental changes; or other ways of altering
the physiology and/or behavior of a live animal. Safety testing is highly regu
lated and is often done after any efficacy testing, if necessary, to finally check
that an intervention is safe for humans and/or other animals to use. Efficacy
testing is less formalized and often occurs in universities as ideas are tested in
live animals as a "proof of concept", often prior to the development of actual
interventions to help humans or other animals.
Methods that replace techniques that use live animals, or methods of test
ing substances without live animal use, are known as alternatives, replacements
or non-animal methods. Some prefer the term advanced technologies given the
fact that they often rely on more sophisticated technology and are more hu
man-relevant than the animal test they replace (see Langley et al., 2015). There
have been efforts to replace animal tests since the 1960s. Significant progress
initially came in replacing animals used to diagnose human disease; to produce
biological drugs (such as vaccines); and to safety test batches of these drugs
as they were produced. Concerns about safety were the initial driver for this,
as drugs produced using animal material could be contaminated with animal
diseases. However, cost, efficiency, and the need for swifter and more accurate
predictions also played a part. Some of the earliest replacements are, in fact, no
longer referred to as such, as they are now standard practice. For example, the
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polio vaccine used to be produced in primary monkey kidney cells, resulting in
the death of tens of thousands of monkeys every year. However, by the 1970s,
the use of long-lived human or monkey cells in culture was common place
and the risk of contamination with animal viruses was also eliminated
(Bookchin and Schumacher, 2005). Batches of the vaccine against yellow fever
used to be tested for efficacy (potency) on animals in lethal dose tests, but
these tests were replaced by a cell culture test, the plaque-reduction neutral
ization test, in the 1970s (World Health Organization, WHO, 2007).
As analytical techniques improved, as well as scientific understanding,
animals were no longer used as indicators of disease because disease-causing
agents were now both understood and could be measured directly. For example,
every batch of insulin used to be checked using 600 mice and tens of thousands
were used in the United Kingdom alone every year. The mouse convulsion test
was a particularly unpleasant test, as the number of mice that went into con
vulsions following injection was used as a measure of the strength of vials of
insulin. Now, analytical methods can measure the components of insulin di
rectly (Underhill et al., 1994). Similarly, rabbits were used in the diagnosis of
pregnancy. A rabbit was injected with the urine from a potentially pregnant
woman, and if the rabbit's ovaries swelled (detected upon killing and dissect
ing the rabbit), this was considered a good predictor of pregnancy (Friedman,
1939). Now, of course, we know that the substance indicative of pregnancy is
gonadotrophin, which can be detected directly using chemical tests.
Nowadays, alternative methods can include a range of techniques, including
cell-based tests (in vitro); tests using tissue taken from dead humans or animals
(ex vivo); chemical-based analytical tests (in chemico ); computer-based model
ling (in silico); and ethical human studies (in vivo). Using examples of these
types of methods used for regulatory safety testing, this chapter illustrates the
difficulties seen in replacing animals and how they can be overcome.

2

Recent Developments in Alternatives to Toxicity Testing

The past 30 years have seen a dramatic increase in the development of alterna
tives to animals (see Liebsch et al., 2011). Advances in replacements are more
recognized in the field of toxicology because it is this area that has received the
most attention. Regulatory, typically toxicity testing, is only a small proportion
of the global testing on animals (8% in Europe according to Daneshian et al.,
2015); but due to the standardized nature of the tests, replacement of just one
test has a permanent effect on the use of animals in that area and is, therefore,
seen as particularly worthwhile.
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Table 24.1 outlines the status of alternatives for the most common tests
used for chemical safety testing, which traditionally and in most cases still use
animals. Two things stand out in this table. First, that replacement of topical
endpoints (i.e., tests that measure effects on the external parts of the body)
are almost completely replaced. However, alternative tests for systemic, broad
effects, such as repeated dose, do not yet feature in the regulatory acceptance
column. Second, there has been significant progress in the past 10 years in reg
ulatory acceptance. Many tests have gained approval from the Organisation for
Economic Co-operation and Development (OECD ), even if they can only be
used in combination with other tests.
TABLE 24.1

Endpoint

Alternatives for standard toxicity tests for chemical safety
Animal test

Alternative tests

Regulatory

acceptance
Skin
absorption

Acute
toxicity

Skin
irritation/
corrosion

Eye
irritation/
corrosion

The substance is rubbed
onto the shaved backs of
rats, and they are killed
the next day ( OECD TG
427).
Rats are exposed to a
very high dose of the
substance, such that
a number of them
are expected to die
(OECD TG 402,403,
420,423,425,436).
Substance is rubbed onto
the shaved backs of rahbits, and they are killed
2 weeks later ( OECD TG
404).
Substance is placed into
the eyes of live rabbits
who are monitored for
up to 3 weeks ( OECD TG
405).

OECD TG 428
Ex vivo skin-based tests that
measure the amount of
(2004). Standalone
substance that passes through replacement.
excised skin.

Cell-based tests, in particular
the NRU 3T3, which measures
the extent of cell death in the
presence of the substance.

Not formally accepted, can be used
in combination with
other information
only.

Reconstituted in vitro human
skin models that measure
the extent of cell death in the
presence of the substance.

431 (2004)
and 439 (2010), plus
others. Testing strategy accepted ( OEcD,
2014a).
OECD TG 437 and
438 ( ex vivo, 2009);
OECD TG 492 (HCE,
2015). Testing strategies yet to be formally
accepted.

Excised eyes from hens and
cattle killed for food ( ex vivo)
can detect non-irritants and
severe irritants; human corneal epithelial (HcE) models
based on excised human skin
or corneas that measure the

OECD TG
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TABLE 24.I Alternatives for standard toxicity tests for chemical safety (cont.)
Endpoint

Animal test

Alternative tests

Regulatory
acceptance

extent of cell death in the
presence of the substance can
detect non-irritants.
Skin
The substance is rubbed Several tests exist that cover
sensitization onto the shaved skin
the adverse outcome pathway
(AOP) for skin allergy. The
of guinea pigs who are
subjectively assessed for direct peptide reactivity ass ay
allergy (Buehler or the
(DPRA) measures the binding
guinea pig maximizaof the substance to proteins
(in chemico); and the
tion test,GPMT; OECD
TG 406); or painted onto in vitro keratinocyte ass ay and
the ears of mice who
the human Cell Line Activaare killed 6 days later to tion Test (h-CLAT), which are
based on human skin cells,
assess the immune response (local lymph node measure part of the immune
assay,LLNA test), (OECD response.
TG 429,442a/b).
Several in vitro tests,including
MutaThe substance is forcegenicity/
fed or injected into mice bacteria (Ames) tests,in vitro
genotoxicity or rats for 14 days; they
chromosome aberration, cell
are then killed to look at micronucleus,and gene mutathe effects on their cells tion tests are available.
(OECD TG 474,475,483, A battery of two or three cellbased tests is always carried
486, 488,489).
out before conducting an
animal test.
Rats (occasionally
Repeated
In silico techniques,such as
dose
rabbits,mice,or dogs)
read across,can be used if the
substance is similar to existing
are force-fed,forced to
inhale,or have the sub- ones that have already been
stance rubbed onto their tested.
A battery of in vitro tests or lab
shaved skin every day
for 28 or go d ays,before on a chip models are still in
being killed (oECD TGs the development phase.
407-413).

OECD TG 442c
(DPRA,2015); 442d
(keratinocyte assay,
2015); and 442e (hCLAT,2016). Testing
strategies yet to be
formally accepted.

OECD TG 471 (1997);
473 (1997); 476
(1997); 487 (2010);
490 (2015). Positive
results,however still
lead to follow up in
vivo.

Read across is accepted on a case-bycase basis (see OECD,
2014b); battery of
in vitro tests or lab
on a chip are not yet
accepted.
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CTA assays have failed
Cell transformation assays
(CTA) based on cellular
nicity
to gain international
regulato ry acceptance
changes to rodent cells have
and are used for
been in use for 50 years and
can detect go% of known hu- screening purposes
man carcinogens.
only (oECD 2015,
2016).
Read across is acReproductive Pregnant female rabbits In silica techniques,such as
toxicity
or rats are force-fed the read across,can be used if the cepted on a case-by
substance and then killed substance is similar to existing case basis (see OECD,
along with their unborn ones that have already been
2014b). EST has
tested.The in vitro Emb ryonic failed to gain inter
babies (oECD TG 414).
Stem cell (EST) test is based on national regulato ry
mouse stem cells. Substances acceptance. Receptor
binding assays ( OECD
are classed as toxic if they
block development into beat TG 455,2012; 457,
2012; 456,2oll) are
ing heart cells.
Other in vitro tests are still in accepted to screen for
potential endocrine
the development phase.
Receptor binding assays are
disrupting properties.
in vitro assays that can detect
activation of genes involved in
hormone production.

Carcinoge

Rats or mice are fed the
substance for two years
to see if they get cancer
(OECD TG 451,452).

For a list of all OECD Test Guidelines referred to in this table, see http://www.oecd.org/chemica
lsafety/testing/oecdguidelinesforthetestingofchemicals.htm.

It is widely acknowledged that public pressure has pl ayed a significant part in
encouraging these developments. Public outrage at animal testing for cosmet
ics started in the 1970s and gained momentum in the 1980s. In Europe, the out
cry turned into calls for an actual ban on cosmetics testing on animals, even in
the absence of alternatives for all relevant animal tests. From 1993, and finally
ending in 2013, a series of deadlines were negotiated and re-negotiated within
the European Union (Eu) by which the testing had to end, first for the testing
of products and then for the testing of ingredients (European Commission,
2017). During this period, the cosmetics industry foresaw that testing any new
substances on animals would soon have to end, and they invested in alterna
tives, as did the European Commission (Ee).
The formal encouragement to use alternatives in the EU was set in stone
by the Eu Directive on animal testing in 1986 ( Council of the European
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Communities, 1986, Directive 1986/609/EE C) and revised in 2010 (European
Parliament, 2010, to Directive 2010/63/EU). Directive 2010/63/EU states that an
animal test must not be conducted if an alternative method is available. This
rule is unique to the EU; and while not enforced as well as one might hope,
it has nonetheless helped encourage the promotion of alternatives interna
tionally. Finally, the overhaul of EU chemicals' legislation in 2006 also pl ayed
a part in driving the need for alternative methods. The new chemical regu
lation, Registration, Evaluation, Authorisation and Restriction of CHemicals
(REACH) is interesting in that it requires the testing of all new and existing
chemicals on animals, unless alternative methods or data already exist (Eu
ropean Parliament and the Council of the European Union, 2006, Regulation
1907 /2006). The fact that this could result in the use of up to 38 million animals
(Joint Research Centre, 2006), has encouraged both regulators and industry to
look for alternatives to keep costs and animal numbers down.

3

Implementation of Alternative Methods

The replacement of an animal test is a laborious and lengthy, scientific and bu
reaucratic process. Figure 24.1 outlines the steps that typically need to be taken
before an animal test can be finally considered replaced by another method.
Unfortunately, the outlined process is often repeated for each sector of use. For
example, the method needs to be validated and accepted for replacing animals
to test chemicals and then repeated in order for the method to be considered
acceptable to replace animals used in drug testing. This is because the types of
chemicals differ in each sector, and there is a fear that the alternative may not
work on different chemistries. There is also an element of distrust in alterna
tives not developed for that sector, and so the industry tends to want to re
evaluate the alternative itself rather than transfer it across immediately.
Development is the stage in which the alternative is created, optimized, and
initially tested. Academe plays a large role at this stage. Alternative centers,
such as the UK National Centre for the 3Rs and alternatives charities, are vital
in funding this kind of work. Researchers may develop spin-off companies to
further develop a method. Larger chemical, medical, and cosmetics companies

Validation
FIGURE 24.I

Formal test
method

Regulatory
acceptance

Deletion of
animal test

The process of acceptance of an alternative test method. Steps in black are
primarily science driven, steps in white are primarily regulatory driven.
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may also develop alternatives, even creating their own spin-off companies or
buying existing ones. For example, L'Oreal purchased the rights to EpiSkin in
1997 and bought the SkinEthic company in 2006, so that they could develop
and use their own human skin irritation models (Auplat, 2012). Unfortunately,
academics may be satisfied by the publication of their method in scientific
journals and often leave it to others to ensure it is used more widely. More pro
active, academic-driven development may still struggle to grasp the regulatory
hurdles that need to be overcome before the method can be used. Unfortunate
ly, industry-driven development can also be rather inward looking. Companies
may be satisfied if the method is considered suitable for their own in-house
purposes for screening substances; and, often, they have little incentive to do
nate the method to the wider community, particularly if they have invested
heavily in its development, and competitors could gain from its use.
Validation is the stage in which the method is independently assessed to en
sure it is reliable and accurate. This step is vital if the method is to progress to
acceptance. There are internationally agreed principles for the way a method
should be validated; but they are rather vague and not always well understood.
The key requirements include, showing that the method produces the same
results when tested at different times in the same laboratory and when used
by other naive laboratories, and that the results are consistent with what is
expected, i.e. the test does what it is designed to do. The process is laborious,
requires collaboration between several laboratories, and can be expensive. If
things go wrong, the validation stage may have to be repeated. In most cases,
historical animal test data is used as the gold standard by which an alterna
tive method is assessed, so no new animal tests have to be done; but there can
be problems in ensuring the old animal data is of good quality. Quite often,
the fact that the animal test itself was never validated causes problems dur
ing validation, as the assessors realize that the animal data is so unreliable or
inaccurate that they cannot trust it (Balls, 2006). Species differences also play
a significant role in making comparisons between human-based cell tests and
animal test results very difficult (Hartung, 2007).
Official bodies are seen as a good way of ensuring a method is correctly vali
dated. In Europe, the European Commission's European Centre for the Valida
tion of Alternative Methods (ECVAM) is an important validation body. There
are now equivalent bodies in other countries, such as the United States (us)
(Interagency Coordinating Committee on the Validation of Alternative Meth
ods, ICCVAM), and Japan (Japanese Centre for the Validation of Alternative
Methods, JaCVAM). Unfortunately, the process of validation and regulatory
acceptance is still a bit of a black box. Methods do not have to go through
these validation centers to be accepted, but it often helps. Companies with
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new methods are often unsure about the process, whether they need to submit
their method for official validation or directly to the regulatory body, who they
should contact, and what information they need to provide.
Formal test method. Once there is sufficient evidence that an alterna
tive method is valid, the next stage is to write up how the method should be
performed as a formal test method. In Europe, the policy is to gain wider agree
ment on the method via large international collaborations, such as the OECD
or the International Council on Harmonization ( I c H ). This is so that the meth
od, in theory, will be accepted outside Europe and European companies will
not be disadvantaged by having to conduct other tests. Negotiating how to con
duct the method is often combined with further analysis of the validity of the
method and can take several years. This stage can also provide false hope that
a method is acceptable in all regions; this is because, although an agreement
may be sought in principle, at an international level, the regional acceptance
process can be prolonged as regulators still have to decide that the method is
relevant and acceptable to the legal framework in their region.
Regulatory acceptance does not automatically happen following the publi
cation of a formal test method, a fact that is often not widely appreciated. Fol
lowing adoption of a formal test method, typically several regional regulatory
agencies have to assess independently whether the method can be used for
their sector (e.g., chemical, medicines, or cosmetics). Unfortunately, there is of
ten no official mandate for them to do this, and they may need political pressure
to act. Regulators do not have to wait until the method is formally recognized
internationally to decide whether they will accept it for their purposes, but they
frequently do. Negotiations within each regulatory body can take many months,
or even years; and currently, these have to happen separately for each sector
and region. Regulators typically accept methods by updating their guidelines,
but it is often only when a corresponding legislation is changed that industry
becomes aware of the need to use the alternative in place of the animal test.
Deletion of the animal test. Changing sector specific legislation to replace
any requirement for a specific animal test with the alternative takes several
years and the process is usually not started until the very end of the process.
Political pressure is usually needed to instigate the deletion of the animal
test, often following pressure from animal protection organizations. For ex
ample, there was a del ay of seven years from the point in which there was a
formal method alternative to the rabbit skin irritation test ( Commission of the
European Communities, 2009) until the rabbit test was deleted from REACH
requirements and replaced with the skin irritation methods (European Com
mission, 2016a). The process was not initiated until 2012, following a complaint
from Cruelty Free International. To date, the rabbit test is still performed in
Europe and elsewhere, and the formal test method for the rabbit test (OECD
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404) still exists. The only standard regulatory animal test that has been de
leted from OEC D requirements is the LD50 acute toxicity test ( OEC D, TG 401)
in 2001, which was "replaced" by other animal tests that cause slightly less suf
fering or equivalent suffering to fewer animals.
Regulatory acceptance is not usually required for methods that replace ani
mals in basic research conducted in academe. Here, the route to acceptance is
a less defined, unofficial, and often very slow process. The scientific communi
ty may gradually move towards alternative methods, usually through the com
mon scientific channels of publications, conferences, and workshops. There is
no body within the medical research establishment tasked with coordinating
this process, although national 3R centers may facilitate more rapid progress
on a case-by-case basis. Regulators of animal experiments could play a role in
ensuring that no animal-based projects are conducted in their region if there
is an alternative; but as the line between what is and what is not an accepted
alternative is less clear for basic research, they currently do not appear to do so.
In summary, the development and validation stages are primarily science
dependent processes, which can be sped up through appropriate funding and
coordination. The stages offormal test method, regulatory acceptance, and dele
tion ofthe animal tests are primarily regulation dependent and can be acceler
ated by political will and regulatory enforcement.
TG

4

The Future of Alternatives

The difficulties of replacing animal tests, combined with increasing frustra
tion with the lack of reliability of animal tests, have forced scientists, in recent
years, to consider whether a paradigm shift is needed. A ground-breaking re
port to this effect was published by the National Academy of Sciences (NAS)
in the us in 2007. Rather than criticizing the ethics of testing on animals, the
report focused on better science and set out a future vision for toxicity testing.
The idea is that society should move away from using black box animal models,
where tests depend on simply counting how many animals die rather than on
understanding why they die. Instead, toxicology should seek to map human
reactions at a more molecular and cellular level, something entirely possible
in vitro. The Toxicology Testing in the 21st Century (ToX21) concept was funded
on a practical level by the us government under the ToxCast project, which is
screening thousands of chemicals using simple in vitro tests to help start the
process of identifying toxicity pathways (Richard et al., 2016).
The NAS report has helped accelerate the concept of Adverse Outcome
Pathways (AOPs) which provides the biological explanation for a single toxic
event. Some toxic events, such as skin irritation and skin sensitization, may
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only have one biological explanation. For example, the AOP for skin sensitiza
tion has been described (OEC D, 2012 ) and is made up of four steps: reaction
of the substance with proteins in the skin, inflammatory responses in kerati
nocyte skin cells, activation of dendritic cells, and lastly the proliferation of T
cells. The first three steps now have OEC D approved in chemico or in vitro tests
(see Table 24.1 ) ; the fourth step is measured in the mouse LLNA.
Unfortunately, some animal tests capture many different types of toxicity,
including some that are not relevant to humans. For example, repeated dose
toxicity tests assess long term toxicity, which can manifest in a number of ways
(e.g. cancer, liver disease, and heart disease, among others). To replace animals
for these tests will require the identification of many AOPs and the develop
ment of tests for the steps within them. The thinking is that if all possible AOPs
relevant to repeated dose toxicity can be mapped, then in chemico or in silico
tests for only some of the key steps will need to be created. The risk is that find
ing all of these AO Ps will take time, and animal tests will not be replaced until
that happens. Nonetheless, the concept has now taken hold in Europe, and the
OEC D is supporting the population of a database of AOPs ( OEC D, n.d.).
Another development in toxicology that seeks to overcome the criticism
that cell cultures are too simplistic, is the lab on a chip concept: body or organ
on a chip models vary in size and complexity but essentially use engineering
technology to combine small cultures of cells ( e.g., liver, brain, and kidney)
into a single, tiny device with fluid running between the compartments of
each type of cell. The idea is to recreate some of the key organs and processes
that occur within a human on a miniature scale (Marx et al., 2012 ) . The concept
is proving not as easy as it seems though, with issues regarding how to remove
waste products, how to keep cells alive, and how to mimic realistic pressures
within the fluidic channels. The lab on a chip and/or the AOP approach will
also likely lead to the replacement of animal models for basic research (Lang
ley et al., 2017 ) . In a way, it should be easier to replace animal tests for drug
development, since drug discovery itself is already very reductionist. New
drugs are usually developed to interact with cell-based mechanisms inside the
body that trigger disease. This is similar to the AO P approach, and it should
be possible to model it in vitro. It is, therefore, rather incomprehensible that
researchers look to a more holistic, whole animal approach to demonstrate
both the efficacy and safety of a new drug, with all the added complications
of lack of relevance and species differences that this brings. Encouraging
researchers to justify efficacy based on human cell-based approaches and then
testing the drug on a few patients in, so calledfutiliry trials (see Creanor et al.,
2015, for example of a futility trial), could be one approach to speed up drug
development and reduce the high number of drugs that fail in clinical trials.
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Another approach is to use technology to enable humans to be used safely
in studies that would otherwise use animals in a harmful manner. Microdos
ing exploits the technological advances in analytical techniques to enable
volunteers to be injected with novel substances at such low levels, that even
potentially harmful substances do not to pose a threat (Lappin, 2015 ) . Simi
larly, improvements in brain imaging technology are enabling researchers to
measure human brain activity non-invasively, and at a high level of precision,
so that invasive tests in monkeys will soon be considered redundant (Bailey
and Taylor, 2016).

5

Barriers to the Implementation of Alternatives and How to
Overcome Them

The Current Scientific Paradigm
A major stumbling block when it comes to replacing animals is the current way
that hypotheses are tested in science. Figure 24.2 outlines the typical process
scientists go through when testing either the safety or efficacy of a substance,
or indeed any hypothesis. The process is one of testing in models of increasing
complexity with growing confidence in the hypothesis, as it successfully passes
each hurdle.
The most common justification for using animals is the apparent need to
test a substance or idea in a "complex, whole being" before there is enough
confidence that it can be tested safely in humans. The assumption behind this
is that the complex, whole being will capture all possible, unforeseen ways in
which the substance or idea could be harmful (or not work), avoiding harm
to (or wasting time on) human volunteers. This "complexity" argument is
one reason for the lack of support for in vitro based techniques, as these are
seen as less complex and, therefore, inferior. The desire to capture all possible
interactions appears to override the very real possibility that many of these
interactions are wrong by the very nature of testing in the wrong species. This
is very frustrating for those who support alternative approaches; and there ap
pears to be a real gap between the two groups in terms of what is more impor
tant, complexity or relevance. Added to that is the fact that demonstration of
5 .1

Test in a simple
- model (computer/in
vitro /DNA screening).
FI GURE 24.2

Test in more
complex model
(animal)

The standard approach to testing medical hyp otheses. Confidence increases as
you move from left to right.
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the predictivity of alternative methods often fails to convince those who can
not get past the fact that the alternative is simply not a live, complex animal.
If an alternative method is found to be go% predictive of effects in humans,
this does not seem to provide confidence. The answer is always, "what if?" This
caution has undoubtedly raised the standard by which alternative methods
are measured; but some believe that the bar is, in fact, now too high and is still
being unfairly applied.
The complexity versus relevance debate may be resolved by greater under
standing and uptake of the AOP approach. This approach seeks to break down
the complexity of biological processes on a more scientific basis. Alternative
methods can be chosen that measure a distinct part of a mechanistic process
that leads to an adverse effect (i.e., toxicity). Using an alternative method that
is known to predict even just one step in the AOP should give confidence that
it is relevant. Combining several methods that test different parts of the AO P
should also help address the complexity issue. Lab on a chip methods, as well
as more complex in vitro methods, such as 3D tissue constructs and mini-brains
(see Caruso, 2017), are also another solution to increase both relevance and
complexity.
Interface with Legislation
Scientists developing alternative methods have historically designed them
to give simple answers to the question, is the substance being tested safe or
toxic, yes or no? This was seen as a good first step to assist in their valida
tion and initial adoption, even if the animal test they are designed to replace
actually produces quantitative (numerical) answers on the extent of toxicity.
However, failure of alternative methods to produce equivalent results to the
animal tests has been one reason for the delay to their full implementa
tion. For example, the in vitro skin irritation/corrosion methods were initially
validated to give a yes/no result on whether a substance would cause skin
corrosion in 1998 (ECVAM Scientific Advisory Committee, ESAC, 1998). This
limited their use because chemical sector regulators actually required these
methods to present the result as not i"itant, i"itant, or severely i"itant/
co"osive. This is because the results of the animal test are used not only for
risk management purposes but for classification and labelling of substances,
which is governed by different legislation. It was not until 2007 that a slightly
different protocol, using the same skin methods, was validated to provide
this information on irritation (ESAC, 2007). Even then, it was not until 2009
(ESAC, 2009)-when a third, more rapid validation was completed because
the classification and labelling requirements had changed since the start of
the process-that the rabbit test was finally replaced using a combination
of two methods.
5.2
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Since the issue surrounding the validation of the skin irritation methods,
there is now greater recognition of the need to be aware of classification and
labelling requirements, but problems still occur. For example, the in vitro skin
sensitization methods were also validated to provide yes/no answers; but the
regulators require three answers: no effect, weak effect, or strong sensitizing. It
was for this reason that the E C and Member States recently refused to remove
the mouse L L NA test from REAC H requirements, as they are of the opinion that
full replacement for classification and labelling is not yet possible using the in
vitro methods (European Commission, 2016b).
The issue is further complicated by countries around the world that have
different requirements for the classification of substances based on the same
toxicity test results. The alternatives are often only validated against one
scheme. For chemicals, this is often the United Nations Globally Harmonized
System (uN G H S) of Classification and Labelling of Chemicals, but this is not
recognized by all countries and all legislations that may have different require
ments. So, two additional hurdles are getting those involved in the validation
of alternative methods to appreciate the regulatory use of the method and
validate it accordingly and getting countries to harmonize their regulatory re
quirements, irrespective of the methods used, to satisfy the requirements. Lack
of international harmonization of classification and labelling requirements is
one of the reasons why rabbit skin irritation tests are still being conducted in
Europe for non-EU regulators, even though the alternatives are now accepted
within Europe.
Bureaucracy
5.3
Bureaucracy plays a large part in the del ay to the implementation of alter
natives, in my view, particularly at the regulatory acceptance stage. Much of
this bureaucracy could be avoided as illustrated below. It is, in my opinion,
in part caused by inertia amongst regulators and a failure to incentivize and
reward them for evaluating new methods. The process still largely relies on the
goodwill of a few experts from a few countries. Industry are not specifically
rewarded for developing alternatives and, indeed, run some risk if the alterna
tive is not accepted (due to wasted development costs). Regulators also run the
risk of accepting a method that could fail in the real world, potentially causing
harm to humans. Hiding behind bureaucratic del ays avoids having to make a
decision.
There are bureaucratic delays caused by the desire to harmonize testing re
quirements internationally. Harmonization is seen as a good thing, as it means
that, in theory, a single (animal) test conducted in a laboratory in one country
will be accepted for regulatory submission of that substance in all countries
that sign on the agreement. This is called Mutual Acceptance of Data (MAD).
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There have been tremendous efforts in the past 20 years to encourage the
chemical and drug sectors to harmonize their requirements. As alternatives
have been developed, they too have had to go through this harmonization pro
cess. In theory, this is also a good thing, because once accepted no more animal
tests would be required around the world for that specific substance. However,
in reality the process of negotiation takes a long time; and to speed up the
process, loopholes are placed in documents that can give a false sense that har
monization has actually been achieved. A recent example is skin sensitization,
where the alternative methods gained OECD acceptance relatively easily, but
on the understanding that they cannot be used as standalone replacements.
Therefore, there is no requirement for countries to accept these methods to
replace the corresponding animal test, until perhaps another formal docu
ment is agreed on at some point in the future that shows how they can be used
together.
In the EU the situation is further complicated. The EU defers to the OECD
on the basis that international harmonization is preferable to EU acceptance
(ignoring the fact that the EU is already a grouping of 28 countries). This causes
on average two years' del ay to a method that was validated in Europe. They
then require that the test method, as agreed by the o E c D, be published in the
official EU regulations (Commission of the European Communities, 2008, Test
Methods Regulation EC440/2008,) in an almost completely bureaucratic pro
cess that takes, on average, a further two to three years. For example, the first
version of the reconstituted skin model was validated by ECVAM for detecting
corrosive substances in 1998 (ESAC, 1998); but it was not adopted by the OECD
until 2004 (OECD, TG 431). The first version of the model for skin irritation
was validated in 2007 (ESAC, 2007); but it was not adopted by the OECD until
2010 (oECD T G 439). Due to political pressure at the time, the EU adopted an
unusual procedure and accepted the skin methods before the OECD in 2000 for
corrosion (European Parliament and the Council of the Eu, 2000), and in 2009
for irritation (Commission of the European Communities, 2009). The EU has
not done this since, even though similar delays have occurred for other meth
ods. For example, the D P RA for skin sensitization was validated in 2012 (ESAC,
2012); but it was not published as OECD T G 44C until 2015. Over two years after
its publication in the OECD, it was published in the EU Test Methods Regula
tion (Commission of the European Communities, 2017).
One could argue that the bureaucratic delay between validation and regu
latory acceptance gives industry time to advance their knowledge of the new
methods, get them into place and gain confidence in their use. In reality, com
panies, other than those directly involved in the development and validation
of the new method, tend to remain unaware of these methods until they are
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accepted. If they do become aware of them, they tend to wait for confirmation
that they will be accepted, before investing in using them. One of the reasons
for the delays at both the 0EC D and the Eu's Test Methods Regulation is the
timing of the cycle for revising test guidelines. The process is annual at the
0EC D; if you miss the deadline for submitting methods, you lose one year. Giv
en sufficient political will, it should be entirely possible to speed up the process
by increasing the cycle of meetings and, in Europe, by accepting that as most
EU members are also members of the 0EC D, there is little need for a second
round of negotiation to update the Test Methods Regulation.
Lack ofFunding
5.4
Obtaining funds to develop replacements for animal tests is still very difficult,
despite a few high profile, one-off, significant projects. For example, in response
to the imminent cosmetics testing bans in 2009, the EC and the cosmetics in
dustry each contributed €25 million towards the development of alternatives
to animals for long-term toxicity testing (SEURAT-1, n.d.). Furthermore, the EC
claims it has funded replacement methods in the last main scientific-funding
stream, Framework Project 7 (2007-2013), to a total of €180 million (European
Commission, 2013). However, compared to overall science funding, the levels
of investment are relatively low. The total Framework Project 7 budget was
€45.3 billion; as such, the Commission dedicated only 0.4°/o of its science bud
get to alternatives to animal testing.
National funding levels are even lower than central funding, perhaps reflect
ing a general apathy about the need to improve the humanity and reliability of
scientific methods. We recently compiled a survey of EU countries and found
that direct funding of alternative (3Rs) methods was reported to total only
€18.7 million in 2013 (Taylor, 2014). Only seven countries provided this funding:
Austria, Belgium, Denmark, Finland, Germany, Sweden, and the UK. Much of
this budget was dedicated to support national centers for the 3Rs rather than
the development of new methods. Funding by the most generous country, the
UK (approximately €11 million), was still only 0.04°/o of its national science re
search and development expenditure for that year.
Central and national funding of alternatives, therefore, exists but is relative
ly very low and ad hoc. This compares poorly to the funding given to equally
ambitious big picture projects. For example, former us President Obama's proj
ect to map the human brain was funded by us$100 million (The White House,
President Barak Obama, n.d.); and the human genome project by us$3.8 bil
lion (Human Genome Research Institute, n.d. ). However, these are single proj
ects. Replacing all animal tests, even only in the field of regulatory toxicology
comprises many, many projects. Clearly, the rate of change is likely to be slow
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unless levels of funding significantly increase and are proportionate to the
scale of the problem being addressed.

Entrenchment
5.5
Many of the remaining animal tests to be replaced, particularly for regulatory
testing, have remained unchanged since they were first developed many de
cades ago. For example, the pyrogenicity test in rabbits (used to establish if
injectable drugs are contaminated) was developed in 1912 (Hort and Penfold,
1912); the Draize skin irritation test on rabbits in 1944 (Draize et al., 1944); and
the Buehler guinea pig skin sensitization test in 1965 (Buehler, 1965).
Entrenchment is common in science (Kuhn, 1962). This may seem counter
intuitive when one considers that what defines science is its questioning na
ture. But even those who use animals in research will attest to the difficulty
in getting funding for new approaches, as well as the difficulty in publishing
research that uses a method that is different from the one everyone else is us
ing. Behind closed doors, researchers will complain about journal editors even
asking for their idea to be demonstrated in an animal model before they will
publish it (see Cronin, 2017; discussions at the recent EC conference on alterna
tives). This situation is partly caused by the fact that those who are conduct
ing research, reviewing papers, and reviewing funding applications are usually
from within the same scientific peer group. New ideas that threaten the status
quo can struggle to gain support; and researchers who are unhappy about their
treatment are often afraid to speak up, in case it affects their university tenure
or funding.
Preferentially funding scientists who want to use different methods is a
system that could work to promote change. However, apart from occasional
large projects, such funding is still only taken on by specialist replacement
charities with small budgets. Once they are a part of a project to replace
animals, however, scientists can create a support network that can help to
foster change; but it is crucial that funding is dependable for this to be sus
tained. Another solution is finding a w ay to include fresh perspectives on the
types of projects being funded. Including experts who are more motivated
to challenge the need to test on animals in the ethical review of projects
involving animals, such as individuals with expertise in alternatives or in
animal protection, could have a big impact. Currently, funding and licens
ing bodies only tend to include token l ay persons in their discussions, who
can feel out of depth and overwhelmed. Making applications or, at the very
least, the funding policies of granting bodies open to regular public scrutiny
could also help.
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Lack ofEnforcement
5. 6
If improved funding of alternatives is the carrot, then enforcement is prob
ably the stick. Although, most would say the carrot is the best approach for
entrenched issues such as this, enforcement still has a role to play. In Europe,
since 1986, it has been illegal, on paper, to conduct an animal test "if another
scientifically satisfactory method of obtaining the result sought, not entailing
the use of an animal, is reasonably and practicably available" ( Council of the
European Communities, 1986, Directive 86/609/EE C). Unfortunately, in 2010
this was watered down, to some extent, with a stricter onus being placed on
methods that are "recognized under the legislation of the Union," although the
general premise remains. "Member States shall ensure that, wherever possible,
a scientifically satisfactory method or testing strategy, not entailing the use of
live animals, shall be used instead of a procedure" (European Parliament, 2010).
Technically the onus is on the Member State to not authorize animal tests
where alternatives exist, rather than on the researcher. Our experience has
shown, however, that if Member States can divest themselves of this, they will.
Laboratories are granted multiple generic licenses that do not cover the specific
substances being tested, which makes it impossible for the authorizing body
to make decisions as to whether an alternative method is suitable. This is a
particular issue with quality control tests, where the alternative can often be
used for some substances and not others. Following an undercover investiga
tion, Cruelty Free International recently demonstrated that a contract testing
facility in the UK was testing substances for pyrogens on rabbits, for which
the alternative bacterial endotoxin test was suitable, according to the Euro
pean Pharmacopeia (see Cruelty Free International, n.d.). It was not until we
challenged the UK competent authority that they began asking for substance
specific information in advance (Animals in Science Regulation Unit, 2014).
Enforcement of the use of alternatives for basic research is more complex
and is currently being largely overlooked by regulators of animal experiments.
Due to the myriad of ways in which animals can be used to test medical hy
potheses, and the lack of formal standardized approaches, regulators tell us
that they cannot really enforce the use of alternatives as they would for safety
testing. Currently, in the UK, the onus is on the researcher, rather than the regu
lator to demonstrate the absence of an alternative approach. The regulator, as
sessing a potential project that intends to use animals, is not usually an expert
in the area; and it is not clear to what extent researchers are really being chal
lenged in their statements that alternatives are not available. The solution is
for regulatory bodies to simply take responsibility for upholding the law when
an alternative method is available that can prevent animal experiments or at
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least partially replace them. Currently, some animal protection organizations
see it as part of their role to hold regulators accountable to encourage them
to do this. A better solution would be if a tougher stance was accepted inter
nally by the regulators, perhaps as a consequence of a directive from their
governments.

6

Targets for Change

It is clear from Table 24.1 that prior to the EU cosmetics testing bans, there was
very little regulatory approval of alternative methods. There is a clear accel
eration from 2003, the date of the implementation of the first testing ban (for
products). But now that Europe has a complete ban on cosmetics testing on
animals, it is important that this momentum is not lost. It is possible that, with
public support, new bans or deadlines could be put in place. There are already
calls for bans on the testing of household products and all testing on dogs and
monkeys. Using prohibitions on testing as an incentive for the development
of alternatives is, however, hitting a hurdle in these areas. Animal testing for
medical purposes is seen as something that cannot end until alternatives are
available, and setting a timeline for science to replace animal experiments is
not considered by some to be possible or even desirable. In a Nature survey of
its readers (over half of whom conducted animal experiments), 63% thought
ending animal experiments was a desirable but unachievable goal (Ainsworth,
2006).
The absence of viable alternatives has, however, not hindered political agree
ment in a number of other areas, where the ability to realize the promise relies
to some extent on science and technology, such as the case of climate change.
Internationally, the Kyoto Protocol was signed by 37 industrialist countries as
well as Europe, in 1997, and set the goal of a 5% reduction in carbon emissions
below 1990 levels by 2012. The target was met (United Nations Climate Change,
n.d. ). Europe has a further commitment to reduce levels by 20% by 2020 (Eu
ropean Commission, n.d.). Although countries have signed up to reduce their
emissions, no one is suggesting that they cease manufacturing cars or tum the
power off in order to do so. Instead, goals to reduce in emissions are being met
by increased efficiency and innovation (see European Commission, n.d.). One
can see that a reduction in animal testing could also be achieved through more
efficient use of animals ( e.g., not authorizing the more "blue sky" type of basic
research and using less animals for any given purpose) and investment in tech
nology. Setting a target of, for example, a reduction of 50% in national animal
experiments by 2025 will enable countries to exert power over experiments
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that they feel they could perhaps do without and to prioritize for replacement
those that they cannot. Targets will feed into the ethical review committees
for animal experiments, who will have to make harder decisions and actually
reject some applications. Targets will also seep into the mindset of scientists,
who will have to think more carefully about whether they are likely to be ac
cepted before putting forward applications for new animal experiments. There
will be more political will to fund alternatives and put in place the necessary
governmental and institutional schemes to fund, develop, promote, and imple
ment alternatives.
It is important to remember that reduction in animal experimentation will
not always rely on replacement. It is unfortunate that this view, however, pre
vails even in Directive 2010/63/EU, which states that "this Directive represents
an important step towards achieving the final goal of full replacement of pro
cedures on live animals for scientific and educational purposes as soon as it
is scientifically possible to do so" (European Parliament, 2010). In the area of
basic research in particular, where the majority of animals are actually used
(Daneshian et al., 2015), there is much more of an element of choice in con
ducting an animal experiment. In a world with infinite questions about hu
man biology, there are equally important questions that can be tackled that
do not require resorting to animal experiments. Some scientists choose to use
animals, but they could choose to study humans, or cells, or computer models
and still contribute to the pool of medical knowledge. If we change the goal to
one of improving the humanity and quality of medical knowledge, rather than
replacing like for like, then, in my opinion, a significant proportion of animal
research could end today.

7

Conclusion

The field of alternatives research has accelerated in the past 30 years, largely
as a result of legislative pressures on specific sectors to end testing and/or use
alternatives. There are now alternatives for a significant proportion of the stan
dard "battery" of animal tests, which are typically required to test the safety
of new chemicals and drugs. Unfortunately, the corresponding removal of the
animal tests that these new alternatives replace is still forthcoming. There are
many reasons why animal testing persists even, when there are alternatives,
which have little to do with the scientific limitations of the new tests. Human
limitations, including bureaucracy, political malaise, and entrenchment in the
scientific establishment are as great, if not greater, barriers to the replacement
of animals in testing.
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There needs to be a paradigm change in the way science approaches many
of its questions. The classic approach of test your idea or substance in a simple
model, such as a cell culture; and then ifsuccessful test it in a more complex mod
el, such as an animal, needs to change. Funding bodies and journals need to
stop requiring proof of concept in animal models but in more human-relevant
approaches. A more mechanistic approach is one possible way to facilitate the
use of alternatives. Breaking down the question you need to answer into ques
tions that can be tested in simpler models would facilitate a speedier uptake of
alternatives. Another approach is to employ technology to overcome some of
the current problems of using humans ethically or to increase the complexity
of cell-based systems. Whether these two approaches will complete or comple
ment each other remains to be seen.
What will encourage science to change its paradigm? Political will needs
to be amplified and targets for a reduction of animal experiments are needed.
This, in tum, will help increase levels of funding to speed up the development
of new approaches and reduce regulatory malaise, so that they are implement
ed as soon as they appear.
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